🔎 Trials Near Me

Inicio › Enfermedad de obstrucción pulmonar crónica › Nueva York

Ensayos clínicos de Enfermedad de obstrucción pulmonar crónica en Nueva York

19 estudios sobre Enfermedad de obstrucción pulmonar crónica buscan participantes en Nueva York.

Ciudades en Nueva York

Texto oficial del estudio (inglés)

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

  • New York Hospital Queens- Site Number : 8400058, Flushing
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 22 sept 2026 · NCT07190209

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

  • Mid Hudson Medical Research - New Windsor- Site Number : 8400004, New Windsor
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 15 sept 2026 · NCT07190222

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

  • Research Site, Mount Kisco
ReclutandoFase 2
Edades de 40 en adelante · Todos los sexos · Actualizado el 9 sept 2026 · NCT07082738

Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

  • Mount Sinai, Icahn School of Medicine, New York
  • Columbia University, New York
  • Cornell University, New York
ReclutandoFase 2
Edades de 40 en adelante · Todos los sexos · Actualizado el 4 sept 2026 · NCT07059091

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

  • Research Site, Staten Island
  • Research Site, Syracuse
  • Research Site, The Bronx
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 3 sept 2026 · NCT06878261

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

  • Research Site, Buffalo
  • Research Site, Cortland
  • Research Site, Horseheads
  • y 2 más
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 3 sept 2026 · NCT06883305

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

  • Northwell Health Physician Partners at Chappaqua, Chappaqua
  • New York Presbyterian Queens, Flushing
  • Northern Westchester Hospital, Mount Kisco
ReclutandoFase 2/3
Edades de 35 a 80 · Todos los sexos · Actualizado el 31 ago 2026 · NCT07363694

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  • Research Site, Albany
  • Research Site, Massapequa
  • Research Site, New Windsor
  • y 3 más
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 26 ago 2026 · NCT06283966

A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP)

  • Equity Medical LLC, New York
ReclutandoFase 1Se aceptan voluntarios sanos
Edades de 18 a 80 · Todos los sexos · Actualizado el 1 jul 2026 · NCT06944925

Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital

  • Icahn School of Medicine at Mount Sinai, New York
Reclutando
Edades de 22 en adelante · Todos los sexos · Actualizado el 23 jun 2026 · NCT07222410

SPIROMICS Study of Early COPD Progression (SOURCE)

  • Columbia University, New York
  • Weill Cornell Medical Center, New York
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 30 a 55 · Todos los sexos · Actualizado el 3 jun 2026 · NCT05033990

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

  • GSK Investigational Site, Mount Kisco
  • GSK Investigational Site, New Windsor
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 9 abr 2026 · NCT06961214

Evaluation Of The Lung Microbiome In NTM Bronchiectasis

  • New York University School of Medicine, New York
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 27 feb 2026 · NCT02779478

Lung Microbiome and Inflammation in Early COPD

  • New York University School of Medicine, New York
ReclutandoEstudio observacional
Edades de 18 a 70 · Todos los sexos · Actualizado el 28 ene 2026 · NCT02777879

PiMZ Longitudinal Cohort (PiMZ Logic)

  • Columbia University Irving Medical Center, New York
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 16 ene 2026 · NCT06505603

Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies

  • Weill Cornell Medical College and Weill Cornell Medical Center, Department of Genetic Medicine, New York
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 nov 2025 · NCT01776398

Comprehensive Patient-Centered Home-based Care Coaching for COPD Self-management

  • Ichan School of Medicine at Mount Sinai, New York
Reclutando
Edades de 40 en adelante · Todos los sexos · Actualizado el 6 oct 2025 · NCT06634810

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

  • Our Lady of Lourdes Hospital, Binghamton
ReclutandoEstudio observacional
Edades de 50 en adelante · Todos los sexos · Actualizado el 5 ago 2025 · NCT06122077

PRagmatic EVAluation of a Quality Improvement Program for People Living With Modifiable High-risk COPD.

  • Mount Sinai, New York
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 oct 2023 · NCT05306743

De ClinicalTrials.gov, datos obtenidos el 30 sept 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.